Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib vs Trastuzumab in HER2+ Metastatic Breast Cancer (CEREBEL)
NCT00820222Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2009
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of lapatinib in HER2-positive metastatic breast cancer, sponsored by Novartis. Started Apr 2009; status: completed.
02
Drugs
lapatinib
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT00820222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00820222.